A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.
Steele, N Anthony, A Saunders, Mark P Esmarck, B Ehrnrooth, E Kristjansen, P Nihlén, A Hansen, L Cassidy, J
Steele, N
Anthony, A
Saunders, Mark P
Esmarck, B
Ehrnrooth, E
Kristjansen, P
Nihlén, A
Hansen, L
Cassidy, J
Citations
Altmetric:
Abstract
Pre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor. This phase 1 trial assessed the safety and tolerability of escalating doses of rIL-21 in combination with cetuximab in chemo-naïve patients with stage IV colorectal cancer.
Description
Date
2012-02-28
Publisher
Collections
Keywords
Type
Article
Citation
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. 2012, 106 (5):793-8 Br J Cancer